The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. (Q46004779)

18 December 2017

title

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. (English)

1 reference

18 December 2017

1 reference

1 reference

1 reference

1 reference

1

1 reference

18 December 2017

Ching-Lung Lai

object named as

Ching-Lung Lai

2

0 references

Yasuhito Tanaka

3

object named as

Yasuhito Tanaka

1 reference

18 December 2017

author name string

Masashi Mizokami

4

1 reference

18 December 2017

John Yuen

5

1 reference

18 December 2017

Danny Ka-Ho Wong

6

1 reference

18 December 2017

Man-Fung Yuen

7

1 reference

18 December 2017

language of work or name

English

0 references

publication date

19 May 2009

1 reference

18 December 2017

The American Journal of Gastroenterology

published in

1 reference

18 December 2017

volume

104

1 reference

18 December 2017

page(s)

1940-6; quiz 1947

1 reference

18 December 2017

issue

8

1 reference

18 December 2017

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Determinants for sustained HBeAg response to lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.200

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.200

1 reference

18 December 2017

PubMed ID

19455108

1 reference

18 December 2017